Results 71 to 80 of about 22,609,350 (346)

Combination of CTLA-4 and PD-1 blockers for treatment of cancer

open access: yesJournal of experimental & clinical cancer research : CR, 2019
Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both ...
Anand Rotte
semanticscholar   +1 more source

CTLA-4

open access: yes, 2019
ALPSOY, ERKAN/0000-0001-7049-0170; uzun, soner/0000-0001-7059-5474; gunasti topal, suhan/0000-0003-0467-5884;
Bacanli, Ali   +6 more
openaire   +2 more sources

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau   +8 more
wiley   +1 more source

Biochemical analysis of CTLA-4 immunoreactive material from human blood

open access: yesBMC Immunology, 2009
Background CTLA-4 was initially described as a membrane-bound molecule that inhibited lymphocyte activation by interacting with B7.1 and B7.2 molecules on antigen presenting cells.
Dennert Kate   +4 more
doaj   +1 more source

Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma

open access: yesCancer Cell, 2023
Summary Immune checkpoint inhibitors (ICIs), including CTLA-4 and PD-1 blocking antibodies, can have profound effects on tumor immune cell infiltration that have not been consistent in biopsy series reported to date.
Katie M. Campbell   +18 more
semanticscholar   +1 more source

Immune Checkpoint Inhibitor–Related Myositis and Associated Triad Overlap Syndrome

open access: yesArthritis Care &Research, EarlyView.
Objective Immune checkpoint inhibitor (ICI) myositis is a rare but a highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all‐cause mortality in these patients.
Selene Rubino   +9 more
wiley   +1 more source

Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas. [PDF]

open access: yesPLoS ONE, 2018
Immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and the programmed cell death protein-1/programmed death-ligand 1 (PD-1/PD-L1) have emerged as promising new targets for cancer therapeutics. While tumor expression of PD-L1 has been
Ari Kassardjian   +2 more
doaj   +1 more source

Different Apples, Same Tree: Visualizing Current Biological and Clinical Insights into CTLA-4 Insufficiency and LRBA and DEF6 Deficiencies

open access: yesFrontiers in Pediatrics, 2021
Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a crucial immune checkpoint that is constitutively expressed in regulatory T (Treg) cells. Following T-cell activation, CTLA-4 is rapidly mobilized from its intracellular vesicle pool to the cell surface to ...
Laura Gámez-Díaz   +2 more
doaj   +1 more source

Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation

open access: yesNature Immunology, 2022
CD28 and CTLA-4 (CD152) play essential roles in regulating T cell immunity, balancing the activation and inhibition of T cell responses, respectively.
A. Kennedy   +20 more
semanticscholar   +1 more source

CTLA-4 gene polymorphisms are associated with obesity in Turner syndrome [PDF]

open access: yes, 2018
Turner syndrome (TS) is characterized by a set of clinical conditions, including autoimmune/inflammatory diseases and infectious conditions, that can compromise a patient's quality of life.
Sergio Crovella (290351)   +41 more
core   +1 more source

Home - About - Disclaimer - Privacy